Therefore, the profile of G6PD and CYP2D6 polymorphisms in this population should be characterized in order to provide information about the safety and efficacy of using 8-aminoquinolines in the treatment of vivax malaria. This evidence concerns the gene CYP2D6 and Plasmodium vivax malaria.